Scientists

Sigilon Therapeutics to Participate in Three Upcoming Investor Conferences

Retrieved on: 
Friday, August 7, 2020
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Diabetes, Clinical trials, Science and technology awards, Scientists, Lemelson–MIT Prize, Robert S. Langer, Awards

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform, today announced that Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in three upcoming virtual investor conferences.

Key Points: 
  • Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform, today announced that Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in three upcoming virtual investor conferences.
  • Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform.
  • The engineered cells are protected by Sigilons Afibromer biomaterials matrix, which shields them from immune rejection and fibrosis.
  • Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Aspen Neuroscience Announces Management Transition

Retrieved on: 
Monday, August 3, 2020
Jeanne Loring, Neuroscience, Neuron, Academic journals, Biology, Scientists

SAN DIEGO, Aug. 3, 2020 /PRNewswire/ -- Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, today announced that Dr. Jeanne Loring, co-founder and Chief Scientific Officer, will transition to the role of Special Advisor to the Company's Research and Development Committee.Dr.

Key Points: 
  • SAN DIEGO, Aug. 3, 2020 /PRNewswire/ -- Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, today announced that Dr. Jeanne Loring, co-founder and Chief Scientific Officer, will transition to the role of Special Advisor to the Company's Research and Development Committee.Dr.
  • Dr. Loring will continue to advise the company's research and development program and contribute to Aspen's patent portfolio.
  • "We are deeply grateful to Dr. Loring for her scientific leadership and dedication to Aspen Neuroscience as the co-founder and Chief Scientific Officer, and we look forward to her continued guidance as Special Advisor, as we advance the first autologous neuron replacement therapy to treat Parkinson disease into clinical trials," said Howard Federoff, M.D., Ph.D., Chief Executive Officer of Aspen Neuroscience.
  • Aspen Neuroscience, Inc., is a development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson disease.

 Healthline to Host Live Town Hall Featuring Dr. Anthony Fauci

Retrieved on: 
Friday, July 31, 2020
Biotechnology, General Health, Infectious diseases, Health, Pharmaceutical, Anthony Fauci, White House Coronavirus Task Force, Coronavirus disease, Scientists, Pseudoscience, Health, Italian people

, will headline a live town hall about the ramifications of COVID-19 on Americans mental health, back to school and other issues related to the pandemic.

Key Points: 
  • , will headline a live town hall about the ramifications of COVID-19 on Americans mental health, back to school and other issues related to the pandemic.
  • Dr. Fauci and the assembled experts are also scheduled to address current concerns about the virus.
  • They will debunk myths and examine conflicting information that the general public may have received about COVID-19 and its spread.
  • In addition to Dr. Fauci, healthcare professionals participating in the town hall will include:

Dr. Anthony Fauci To Appear On WebMD

Retrieved on: 
Wednesday, July 15, 2020
Anthony S. Fauci, Fauci, Scientists

NEW YORK, July 15, 2020 /PRNewswire/ -- Dr. Anthony Fauci , Director of the National Institute for Allergy and Infectious Diseases, is scheduled to appear on WebMD, the world's leading source for trustworthy medical information and timely health news, this Friday, July 17, 2020, speaking with Dr. John Whyte , WebMD's Chief Medical Officer.

Key Points: 
  • NEW YORK, July 15, 2020 /PRNewswire/ -- Dr. Anthony Fauci , Director of the National Institute for Allergy and Infectious Diseases, is scheduled to appear on WebMD, the world's leading source for trustworthy medical information and timely health news, this Friday, July 17, 2020, speaking with Dr. John Whyte , WebMD's Chief Medical Officer.
  • Dr. Fauci will discuss the troublesome uptick in COVID-19 cases sweeping parts of the country, how experts can better communicate risk (including to young people), and how it is possible to get past this crisis and live with the virus without returning to lockdowns while waiting for an effective vaccine.
  • The full interview will be available online at www.WebMD.com beginning at 9:30 AM ET this Friday.

Glympse Bio Announces $46.7 Million Series B Financing

Retrieved on: 
Wednesday, July 15, 2020
Hepatitis, Life sciences, Medicine, Steatohepatitis, Biotechnology, Non-alcoholic fatty liver disease, Sangeeta, Bhatia, Nash, Biosensor, Scientists

CAMBRIDGE, Mass., July 15, 2020 /PRNewswire/ -- Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, has closed an oversubscribed $46.7 million Series B financing.

Key Points: 
  • CAMBRIDGE, Mass., July 15, 2020 /PRNewswire/ -- Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, has closed an oversubscribed $46.7 million Series B financing.
  • In connection with the financing, Steven Kafka, Ph.D., Managing Partner at Section 32, and George Zachary, General Partner at CRV, will join the Glympse Board of Directors.
  • The proceeds from the financing will support continued development of Glympse's novel biosensor platform in Non-Alcoholic Steatohepatitis (NASH), a disease that impacts 16 million people in the U.S. and 100 million worldwide.
  • Founded in 2015, Glympse Bio is an MIT spin-out from the laboratory of renowned bioengineer, Dr. Sangeeta Bhatia.

Beckman Foundation Announces 2020 Arnold O. Beckman Postdoctoral Fellows

Retrieved on: 
Thursday, June 18, 2020
Businesspeople, California Institute of Technology faculty, Awards, Arnold Orville Beckman, Beckman, Scientists, Anne Hultgren, Beckman Fellow, Beckman Institute

IRVINE, Calif., June 18, 2020 /PRNewswire-PRWeb/ -- The Arnold and Mabel Beckman Foundation announced today its 2020 class of Arnold O. Beckman Postdoctoral Fellows in Chemical Sciences, individuals who underscore the Foundation's mission of supporting basic research in the chemical sciences and chemical instrumentation.

Key Points: 
  • IRVINE, Calif., June 18, 2020 /PRNewswire-PRWeb/ -- The Arnold and Mabel Beckman Foundation announced today its 2020 class of Arnold O. Beckman Postdoctoral Fellows in Chemical Sciences, individuals who underscore the Foundation's mission of supporting basic research in the chemical sciences and chemical instrumentation.
  • The Foundation will award more than $4 million in funding over the next three years for 14 exceptional research fellows from 7 universities:
    "We are so proud to support these young scientists as they begin their transition to independent research careers," shared Dr. Anne Hultgren, Executive Director of the Arnold and Mabel Beckman Foundation.
  • Congratulations to the 2020 class of Arnold O. Beckman Postdoctoral Fellows!"
  • Located in Irvine, California, the Arnold and Mabel Beckman Foundation supports researchers and nonprofit research institutions in making the next generation of breakthroughs in chemistry and the life sciences.

Beckman Foundation Announces 2020 Beckman Young Investigator Awardees

Retrieved on: 
Thursday, June 11, 2020
Awards, Businesspeople, Arnold Orville Beckman, California Institute of Technology faculty, Beckman, Scientists, Anne Hultgren, Beckman Institute, Beckman Fellow

IRVINE, Calif., June 11, 2020 /PRNewswire-PRWeb/ -- The Arnold and Mabel Beckman Foundation announced today the selection of its 2020 class of Beckman Young Investigator Awardees from U.S. colleges and universities.

Key Points: 
  • IRVINE, Calif., June 11, 2020 /PRNewswire-PRWeb/ -- The Arnold and Mabel Beckman Foundation announced today the selection of its 2020 class of Beckman Young Investigator Awardees from U.S. colleges and universities.
  • This year's award offers $600,000 in funding over four years to each of the following researchers:
    "Our newest Beckman Young Investigator awardees are inspired to address global issues through their research, such as rapid vaccine development, understanding methane-consuming bacteria, and re-imagining chemical manufacturing processes," shared Dr. Anne Hultgren, Executive Director of the Arnold and Mabel Beckman Foundation.
  • Located in Irvine, California, the Arnold and Mabel Beckman Foundation supports researchers and nonprofit research institutions in making the next generation of breakthroughs in chemistry and the life sciences.
  • Founded in 1978 by 20th century scientific instrumentation pioneer Dr. Arnold O. Beckman, the Foundation supports United States institutions and young scientists whose creative, high-risk, and interdisciplinary research will lead to innovations and new tools and methods for scientific discovery.

Quadriplegic Scholar Contradicts Stephen Hawking, Says, ‘There is a God’ in New Book

Retrieved on: 
Tuesday, June 2, 2020
Popular science books, Scientists, Science, Physicists, Cosmologists, Stephen Hawking, Transhumanists, Brief Answers to the Big Questions, Perepelkin, God, Hawking

In his new book, YHWH and the Sacred Secret, readers will experience Perepelkin reversing Stephen Hawkings stance on There is no God.

Key Points: 
  • In his new book, YHWH and the Sacred Secret, readers will experience Perepelkin reversing Stephen Hawkings stance on There is no God.
  • No one directs the universe, which Hawking expressed in his final book, Brief Answers to the Big Questions.
  • From one quadriplegic to another, I have a great deal of respect for Stephen Hawking, writes Perepelkin.
  • My whole life I wondered if there was a God or something to explain why we are here, said Perepelkin.

2020 Borlaug CAST Communication Award goes to Alexa Lamm

Retrieved on: 
Tuesday, May 12, 2020
Awards, National academies, Scientists, American Council on Science and Health, Mexican Academy of Sciences, Norman Borlaug, University of Minnesota, Borlaug CAST Communication Award, Lamm, Alison Van Eenennaam

AMES, Iowa, May 12, 2020 /PRNewswire-PRWeb/ -- The Council for Agricultural Science and Technology (CAST) announces that the 2020 Borlaug CAST Communication Award goes to Alexa Lamm, an Associate Professor of Science Communication at the University of Georgia.

Key Points: 
  • AMES, Iowa, May 12, 2020 /PRNewswire-PRWeb/ -- The Council for Agricultural Science and Technology (CAST) announces that the 2020 Borlaug CAST Communication Award goes to Alexa Lamm, an Associate Professor of Science Communication at the University of Georgia.
  • Lamm won the National Researcher Award from the American Association of Agricultural Education in 2019, and she has received recognition and awards in many areas including extension, agricultural leadership, education, and communication.
  • Lamm now joins ten other respected and talented science communicators in receiving an award that honors the legacy of Norman Borlaug.
  • The Borlaug CAST Communication Award honors the legacies of Nobel Prize winner Dr. Norman Borlaug and Dr. Charles A.

Compugen Reports First Quarter 2020 Results

Retrieved on: 
Wednesday, May 6, 2020
Compugen, Anat Cohen-Dayag, Companies, Science and technology in Israel, Cancer immunotherapy, Scientists

HOLON, Israel, May 6, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapycompany and a leader in predictive target discovery, today reported financial results for the first quarter ended March 31, 2020.

Key Points: 
  • HOLON, Israel, May 6, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapycompany and a leader in predictive target discovery, today reported financial results for the first quarter ended March 31, 2020.
  • "We have entered 2020 well positioned and with significant momentum to advance our clinical programs that address novel, internally-discovered, drug targets for cancer immunotherapy," said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen.
  • Research and development expenses for the first quarter ended March 31, 2020 were $4.7million, compared with $6.3 million in the comparable quarter in 2019.
  • The Company will hold a conference call today, May 6, 2020, at 8:30 AM ET to review its first quarter 2020 results.